Acacia Pharma : Jefferies London Healthcare Conference Presentation

Acacia Pharma Group plc

Jefferies London Healthcare Conference Presentation November 2021

Delivering innovative products to enhance surgical patients' recovery

Important Notice

The information contained in this presentation (this "presentation") has been prepared by Acacia Pharma Group plc ("the Company") as at the date of this presentation and is subject to updating, completion, revision, further verification and amendment without notice. This presentation is for general information only and is the property of the Company. Making this presentation available in no circumstances whatsoever implies the existence of a commitment or contract by or with the Company, or any of its affiliated entities, or any of its or their respective subsidiaries, directors, officers, representatives, employees, advisers or agents for any purpose.

This presentation has not been approved by the United Kingdom Listing Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000 ("FSMA")), by the Belgian Financial Services and Markets Authority or otherwise, by the regulated market of Euronext Brussels. This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or on the completeness, accuracy or fairness thereof.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or its directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements, negligence or otherwise for any other communication written or otherwise. In addition, in issuing this presentation, the Company undertakes no obligation to update or to correct any inaccuracies which may become apparent in this presentation. Notwithstanding the aforesaid, nothing in this paragraph shall exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.

The statements contained in this presentation may include "forward looking statements" that express expectations of future events or results. All statements based on future expectations rather than on historical facts are forward looking statements that involve a number of risks and uncertainties and the Company cannot give assurance that such statements will prove to be correct. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. The Company gives no undertaking to update forward looking statements to reflect any changes in expectations, events, conditions or circumstances upon which such statements are made.

The presentation should not be considered a recommendation by the Company or any of its affiliated entities, or any of its or their respective subsidiaries, directors, officers, representatives, employees, advisers or agents in connection with any purchase of or subscription for securities of the Company.

This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, this presentation should not be copied or distributed by recipients and should not be distributed by any means including electronic transmission, to persons with addresses in the United States of America, Canada, Australia, South Africa or Japan their possessions or territories or to any citizens thereof, or to any corporation, partnership or such entity created or organised under the laws thereof. Any such distribution contrary to the above could result in a violation of the laws of such countries.

2

Acacia Pharma Group - Overview

BARHEMSYS® - FDA approved for PONV, launched late 2020

• Broad label for prevention and treatment of Post-Operative Nausea and Vomiting (PONV)
• Only agent approved for 'Rescue' of ~16m patients p.a. in US with PONV after generic antiemetics fail1
• PONV "rescue" is an estimated $2.7 billion annual total addressable market2

BYFAVO® - In-licensed, FDA approved for procedural sedation, launched Jan 2021

• Indicated for procedural sedation in adults - launch benefitting from shared value proposition
• Key target: 40m procedures a year in US, including 25m GI procedures3
• Estimated >$1.5 billion annual total addressable market4

Commercialization and engagement with KOLs showing good progress

• Strong, experienced team has effectively engaged with customers both virtually and live when possible
• Customers have provided very positive feedback on their initial experiences with the products
• Initiated the Byfavo pediatric study and have seen significant KOL interest in further studying Byfavo
• Partnering with key institutions to begin the Barhemsys PROMPT study to gather real-world evidence

1 Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses as follows: National Hospital Discharge Survey, 2006; National Survey of Ambulatory Surgery, 2006 (as revised in 2009); Source Healthcare; NCHS 2005; Life Science Strategy Group, LLC Market Research; Apfel et al.,2004. 2 Based on the calculations in (1) multiplied by the number of doses per patient at a WAC price of $85 per 10mg dose. 3 iData Research, US Market Report

3 Procedure Numbers for Gastrointestinal Endoscopic Devices February 2019; American Society of Anesthesiologists, Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018; and Quantitative Market Research prepared by The Link Group for Cosmo Technologies (March 2019). 4 Based on the calculation in (4) multiplied by the number of doses per patient at a WAC price of $39 per dose.

Leadership Team with Experience to Deliver the Vision

Mike Bolinder

CEO

Gary Gemignani

CFO

Deb Hussain

CCO

Dr Gabriel Fox

CMO

• Joined 2015, became CEO 1 August 2019
• 20 years experience in life sciences
• Relevant commercial experience with OFIRMEV® at Cadence/Mallinckrodt
• Joined as CFO January 2020
• 30+ years finance experience in healthcare
• Relevant CFO experience in early commercial stage pharma
• Joined as CCO May 2021
• 20+ years in pharma sales & marketing
• Relevant commercial launch experience with multiple pharma brands
• Joined as CMO 2008
• 24 years in pharmaceutical medicine
• Relevant development and medical- marketing experience in repurposed drugs

4

We have been able to make significant progress in a very challenging operational environment caused by the global pandemic

		The OR accounts for up to 65% of hospital
		profit margin, so this missing volume is
		cutting deeply into cash flow and net income.
		- Becker's Hospital Review1
	COVID-19 impact on	• Non-essential surgeries cancelled creating a significant backlog
	hospitals and surgical	• Physical access to hospital decision-makers even more restricted
	centers
	Hospital profits have	• Surgeries and procedures are major contributors to hospital profits
	suffered and need to be
	• Providers need to dramatically increase throughput to regain lost profits
	restored quickly

We believe our products and team are ideally positioned to help

• BARHEMSYS and BYFAVO can help improve patient throughput - both are now even more relevant and of greater interest to customers due to COVID
• Our strong relationships are helping us gain access to key decision-makers

5	1 How to rebuild surgical revenue afterCOVID-19,Becker's Hospital Review, accessed viahttps://www.beckershospitalreview.com/strategy/how-to-rebuild-surgical-
revenue-after-covid-19-even-if-you-just-lost-60-of-your-or-volume.html